InMed Pharmaceuticals Inc. — Form 8-K

Mentari Therapeutics, Inc. announced a $200 million private placement (Amendment No. 1 to Securities Purchase Agreement dated July 22, 2026) consisting of common stock and pre-funded warrants from investors including Fairmount, ADAR1 Capital Management, Venrock Healthcare, Sirenia Capital, Janus Henderson, Blackstone, RTW Investments, Deep Track Capital, Vivo Capital, Commodore Capital, and BB Biotech. The placement is expected to close concurrently with Mentari's previously announced $290 million private placement and immediately before completion of its merger with InMed Pharmaceuticals (Nasdaq: INM). Combined, these financings will extend Mentari's cash runway to 2029 and fund Phase 2a readouts for migraine prevention pipeline programs MT-001 and MT-002. Post-merger, estimated total shares outstanding on an as-converted/as-exercised basis will be approximately 601.2 million.